The Development of a Common European Case Law on Liability for Drugs Stefan Lenze, BIICL, Lovells.

Slides:



Advertisements
Similar presentations
Environmental Law and Policy
Advertisements

© Safeguarding public health Expert Group on Innovation in the Regulation of Healthcare products Adaptive Licencing workshop at the Wellcome Trust October.
What about a future European Safety Act ? June 8, 2012 Noëlle Lenoir.
EU Cross-Border Care Directive from the Primary Care perspective Results of a simulation Rita Baeten Gothenburg, 3 September 2012.
Chapter 4 Inside Criminal Law
The fundamentals of EC competition law
Prof. Dr. Sabine Schlacke Institute for Environmental and Planning Law The Europeanization of the access to justice in environmental matters – the German.
PUBLIC POLICY, DOCTRINAL ORTHODOXY AND THE FUTURE OF MEDICINAL PRODUCT LIABILITY Dr Richard Goldberg Director, Institute of Medical Law School of Law University.
Onscreen cover – Alternative 5 Joint and several liability for cartel fines: lessons from Gigaset and Siemens Austria 73 TH LUNCH TALK OF THE GCLC Winfred.
Nabarro Nathanson Workshop on Software Quality and the Legal System Friday 13th February 2004 Safety Related Systems: The Legal Framework Dai Davis Solicitor.
ENVIRONMENTAL LIABILITY IN GREECE THE LEGAL FRAMEWORK & THE ROLE OF FINANCIAL GUARANTEES/ INSURANCE PRODUCTS TO COVER OPERATORS’ RESPONSIBILITIES UNDER.
Medico-legal aspects of “off-licence” prescribing in Obstetrics ENTER 2006 CONFERENCE Saj Shah Solicitor/Pharmacist 3 May 2006.
Libby McVeigh Fair
European Parliament Advanced Therapies Hearing May 11, 2006 Advanced Therapies The proposed EU regulation from the viewpoint of a Pharmaceutical company.
 Governmental power and functions in the United States rest in 3 branches of government:  Legislative Branch:  Article I of the Constitution  Executive.
© OECD A joint initiative of the OECD and the European Union, principally financed by the EU Public Procurement Review and Remedies in the Member States.
ICPHSO: U.S. and Canadian Product Liability and Safety Regulatory Risks Kenneth Ross Bowman and Brooke LLP October 27, 2009.
How does the ECA assess Member States’ internal control systems? Workshop on Audit/Evaluation of Public Internal Financial Control Systems (PIFC) Ankara,
EUROPEAN COMMISSION - DG Internal Market 1 "Reviewing the Review: The European Commission's Third Review of the Product Liability Directive"
Product liability. Background Product liability in the EU prior to the directive –Tort law – fault based liability –Contract law Only available to parties.
Ole Kr. Fauchald Introduction to biodiversity n What is ”biodiversity”? ä Distinguish between levels of biodiversity ä Development of biodiversity.
Draft Model Rules for EU Administrative Procedures – History, Concept, Principles and Scope Book I – General Provisions Presentation for the EU Ombudsman.
SOURCES OF LAW A (very) BRIEF OUTLINE. SOURCES Common Law Equity Legislation – from UK and EU.
Implementation Challenges of Access to Justice in Europe C s a b a K i s s TAI EMLA Justice and Environment.
1 Unit 5 Torts ARE Definition n Civil Wrong.
Regulators’ response to consultation on EU legislative proposals for pharmacovigilance : common themes 2 nd International Pharmaceutical Regulatory and.
© OECD A joint initiative of the OECD and the European Union, principally financed by the EU. Trends and Features in the Review and Remedies System in.
Defining and applying mitigating and aggravating circumstances. Relevant changes to the amount of fine. Defining and applying mitigating and aggravating.
Recent developments in EU legislation relevant to the future development of article 6 of the Aarhus Convention European Commission, DG Environment, A2.
European Parliament: Location and composition It is located in Strasbourg (France). After the Lisbon Treaty no country can have less than 6 members and.
Directorate General for Enterprise and Industry European Commission The New Legislative Framework - Market Surveillance UNECE “MARS” Group meeting Bratislava,
Support for the Modernisation of the Mongolian Standardisation system – EuropeAid/134305/C/SER/MN Training on standardisation Support to the Modernisation.
Principles of European Tort Law A Critical Examination Ken Oliphant (Cardiff Law School) BIICL, 23 November 2005.
Economics, uncertainty, rule-making and judicial review lessons from EU will competition law Moscow - April 2015
British Institute of International and Comparative Law “ 'Reviewing the Review: the European Commission's Third Review of the Product Liability Directive.'
Protection against the „new” risks “adequately solving the problem, peculiar to our age of increasing technicality, of a fair apportionment of the risks.
Opt in vs. Opt out Emmanuel Gybels. 2 Introductionary remark : there is not one answer to this question – approach varies depending on type of claim and.
British Institute for International & Comparative Law Product Liability & Mass Torts in a Global Marketplace London – 7 June 2007 Regulation and Product.
Thomas Fleiner: Class No. 7 Different Systems of Constitutional Review Belgrade Law Faculty Master Course on Comparative Constitutional Law Prof. Thomas.
Cases C-401 to 403/12 and C-404 to 405/12: No review of legality in light of the Aarhus Convention Dr. Mariolina Eliantonio, LL.M. Prof. Chris Backes Maastricht.
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
Rosemarie Bernabe, PhD Julius Center for Health Sciences and Primary Care Patient representatives’ contributions to the benefit-risk assessment tasks of.
Date: in 12 pts MARKET SURVEILLANCE IN THE EU ROLE IN THE NLF - EU ACTIONS and DEVELOPMENTS Rita L'Abbate European Commission DG ENTERPRISE AND INDUSTRY.
 Why does environmental policy differ across countries?  Why doesn’t science necessarily lead to convergent outcomes?  What is the relationship of science.
‘The effect of legal rules on innovation: A theoretical framework and research agenda’ Prof. Tsachi Keren Paz ‘Liability v Innovation’: Seminar Two Keele,
Corporate Criminal Liability
SOURCES OF LAW A (very) BRIEF OUTLINE.
▸ Agustín Reyna Conference dedicated to European Consumer Day Vilnius
Theories of Tort Law.
NMO Environmental Enforcement
Pre-trial detention decision-making: A European research project
English for Lawyers 3 Lecturer: Miljen Matijašević
Antitrust Follow on Litigation: Europe Plays Catch-up
The Mutual Recognition Regulation
Cybersecurity: the consumer perspective
Bart van der Sloot Data Protection 2.0 The proposal for a General Data Protection Regulation Bart van.
Bart van der Sloot Data Protection 2.0 The proposal for a General Data Protection Regulation Bart van.
Constitutional Review Prof. Lidija Basta Fleiner Prof. Thomas Fleiner
The European Anti-Corruption Report
醫療過失:因果關係 楊智傑.
Commission strategy to
It was Twenty Years Ago Today
European Trends in Pharmaceutical Litigation and Regulation
European Trends in Pharmaceutical Litigation and Regulation
The Aarhus Convention and the Access to Justice Pillar: Introduction to Article 9. 1 Stephen Stec Tirana, November 2008.
Democracy in the EU.
European Commission, DG Environment
Alexandre Regniault Avocat à la Cour Simmons & Simmons
SUBSTANTIVE LAW “LIVE” CLASS for TORTS
Presentation transcript:

The Development of a Common European Case Law on Liability for Drugs Stefan Lenze, BIICL, Lovells

The Case Law on the Directive European Court of Justice 5 National Courts about 100 relevant decisions –UK 7 –France 7 –Spain 20 –Germany 25 –Austria over 50 Supreme Court decisions alone Decisions on pharmaceuticals 3 –2 on infected blood (A v National Blood Authority; Scholten) –1 tranquilizer (Halcion)

Roadmap for courts in shaping the law on liability for drugs Risk-benefit analysis Regulatory compliance defence Development risks defence Warnings: the role of the learned intermediary Causation

Risk-benefit analysis and PLD shortcomings of expectations test legitimate expectations ≠ not actual expectations pharmaceuticals - a special case -public perception of risk is inadequate -harmonization with regulatory framework -DTI Explanatory Note German Drug Act (r/b) seen to be in line with PLD -Halcion case

Risk-benefit analyis and PLD (2) Directive: “ … all circumstances … including…” A v National Blood –All “relevant factors” –Important factors are listed: German Directive: “insbesondere”; French Directive: “notamment” –Risk-benefit would be an important factor but is not listed Why A v National Blood is wrong: –Misinterpretation of German and French Directive –Only unimportant factors could be considered: are they relevant? –Materials from the legislative process  Listed factors are just examples A v National Blood concerns manufacturing defect (non- standard product)

Risk-benefit analysis in action The regulatory approach -Assessment on basis of pre-marketing knowledge (reviews) -Suspected harmful effects v prospective benefits -Absolute-risk benefit analysis Possible approach of the Directive -Knowledge at time of trial (  Art. 7 e) -Regulatory environment at the time of circulation (  Art. 6 (1) c)  Alternative therapies -Proven harmful effects v benefits -“Good for any class of patients” (US Third Restatement)? -Limits of judicial decision-making? -not as to pharmaceuticals

Regulatory compliance defence Debate at EU Level –Suggestions by industry groups –Commission and national governments very sceptical about automatic defence –Discussed before adoption Directive Part of the defect rule –BIICL database (e.g. German case law)

Causation under the Directive Causation as an element of the PLD -General causation is part of defect rule in Article 6 PLD -Specific causation -Substantive law: Article 1 PLD -Burden of proof: Article 4 PLD -Standard of proof: national law Material contribution/increased risk: substantive law concept Loss of chance: substantive law concept Uncertainty over producer (Fairchild): substantive law concept Reversal of burden of proof in new German Drug Act contravenes Article 4

Solution for courts (and lawyers) Comparative Law  European Court of Justice does it  National Courts do it -A v National Blood Authority (PLD) -Fairchild (Negligence) -Austrian and German decisions  BIICL Database has it

“There is law elsewhere!” - Lord Bingham -